Objective: To investigate efficacy of azelastine hydrochloride combined with montelukast sodium in the treatment of patients with allergic rhinitis.
Methods: A total of 137 patients with allergic rhinitis in our hospital were divided into two groups, 70 patients in the experimental group received azelastine hydrochloride combined with montelukast sodium treatment, while 67 patients in the control group were given only azelastine hydrochloride treatment. The clinical therapeutic effect, clinical symptom score and serum levels of inflammatory factors were recorded.
Results: The clinical therapeutic effect of the two groups after treatment were improved compared to those without intervention (P < 0.05), and the total effective rate of the experimental group was 94.3% (66/70), which was higher than that of the control group (83.6%). The clinical symptom score (nasal itching, nasal congestion and runny nose) of two groups was decreased after receiving the intervention, and the scores in the experimental group were much lower than the control group after receiving the intervention (P < 0.05). The serum levels of inflammatory factors (IL-6, IL-8 and hsCRP) were obviously lower in the two groups after treatment, and those levels in the experimental group were much lower than the control group after receiving the intervention. Furthermore, after the receiving treatment, the levels of each of the inflammatory and anti-inflammatory factors in the experimental group were significantly ameliorated compared to those in the control group (P < 0.05).
Conclusion: Azelastine hydrochloride combined with montelukast sodium can effectively improve clinical symptoms and inflammatory reactions in patients with allergic rhinitis; furthermore, this research provides ideas for clinical practice.
Keywords: Azelastine hydrochloride; allergic rhinitis; montelukast sodium.
AJTR Copyright © 2021.